Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of litifilimab in adults with active systemic lupus erythematosus on non-biologic standard therapy
CTR20221351Phase 3Active
- Sponsor
- Biogen
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of litifilimab in systemic lupus erythematosus (SLE), sponsored by Biogen. Started Mar 2023; status: active.
02
Drugs
litifilimab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on CTR20221351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221351.